• 
  L. Veloza, Doriane Cavalieri, E. Missiaglia, Albane Ledoux-Pilon, B. Bisig, et al.. Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome.. Haematologica, 2022, Haematologica, 108, ⟨10.3324/haematol.2022.281226⟩. ⟨hal-04567336⟩
• 
  Emeline Tabouret, Caroline Houillier, Nadine Martin-Duverneuil, Marie Blonski, Carole Soussain, et al.. Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial. Neuro-Oncology, 2016, 19 (3), pp.now238. ⟨10.1093/neuonc/now238⟩. ⟨hal-04406451⟩
• 
  Stéphane Culine, Aude Fléchon, Gwenaelle Gravis, Guilhem Roubaud, Yohann Loriot, et al.. Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study. Clinical Genitourinary Cancer, 2021, 19 (4), pp.e216-e222. ⟨10.1016/j.clgc.2021.02.005⟩. ⟨hal-03631553⟩
• 
  Elise Dumas, Lucie Laot, Florence Coussy, Beatriz Grandal Rejo, Eric Daoud, et al.. The French Early Breast Cancer Cohort (FRESH): A Resource for Breast Cancer Research and Evaluations of Oncology Practices Based on the French National Healthcare System Database (SNDS). Cancers, 2022, 14 (11), pp.2671. ⟨10.3390/cancers14112671⟩. ⟨hal-03901737⟩
• 
  Patrick Robelin, Michel Tod, Olivier Colomban, Joel Lachuer, Isabelle Ray-Coquard, et al.. Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study). Gynecologic Oncology, 2020, 159, pp.256 - 263. ⟨10.1016/j.ygyno.2020.07.021⟩. ⟨hal-03491450⟩
• 
  Rémy Duléry, Sylvain Lamure, Marc Delord, Roberta Di Blasi, Adrien Chauchet, et al.. Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy. American Journal of Hematology, 2021, 96 (8), pp.934-944. ⟨10.1002/ajh.26209⟩. ⟨hal-03401859⟩
• 
  Florence Lerebours, Marc Espié. Le risque hormonal : sa place par rapport aux autres risques de cancer du sein Existe-t-il un profil de risque en France ?. 26èmes Journées de la Société française de sénologie et de pathologie mammaire (SFSPM), Nov 2004, Nancy, France. pp.90-101. ⟨hal-03573669⟩
• 
  Pascal Pujol, Catherine Noguès, Anne Lesur, Pascale This, Dominique Stoppa-Lyonnet, et al.. Hormonothérapie chez la femme porteuse d'une mutation BRCA 1 ou 2. 26èmes Journées de la Société française de sénologie et de pathologie mammaire (SFSPM), Nov 2004, Nancy, France. pp.372-385. ⟨hal-03573648⟩
• 
  Frédérique Spyratos. Protéomique et cancer du sein : en théorie et en pratique. 26èmes Journées de la Société française de sénologie et de pathologie mammaire (SFSPM), Nov 2004, Nancy, France. pp.46-53. ⟨hal-03573601⟩
• 
  Laura Rozenblum, Fatima-Zohra Mokrane, Randy Yeh, Mathieu Sinigaglia, Florent L Besson, et al.. Imaging-guided precision medicine in non-resectable gastro-entero-pancreatic neuroendocrine tumors: A step-by-step approach. European Journal of Radiology, 2020, 122, pp.108743. ⟨10.1016/j.ejrad.2019.108743⟩. ⟨hal-02988286⟩
• 
  Marie-Helene Delfau-Larue, Marie-Laure Boulland, Asma Beldi-Ferchiou, Pierre Feugier, Hervé Maisonneuve, et al.. Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study. Blood Advances, 2020, 4 (14), pp.3217-3223. ⟨10.1182/bloodadvances.2020001955⟩. ⟨inserm-03498367⟩
• 
  Maia Chanrion, Inna Kuperstein, Cédric Barrière, Fatima El Marjou, David Cohen, et al.. Concomitant Notch activation and p53 deletion trigger epithelial-to-mesenchymal transition and metastasis in mouse gut. Nature Communications, 2014, 5, pp.5005. ⟨10.1038/ncomms6005⟩. ⟨hal-01712223⟩
• 
  Gilles Houvenaeghel, Eric Lambaudie, Jean-Marc Classe, Chafika Mazouni, Sylvia Giard, et al.. Lymph node positivity in different early breast carcinoma phenotypes: a predictive model. BMC Cancer, 2019, 19 (1), pp.45. ⟨10.1186/s12885-018-5227-3⟩. ⟨hal-01983749⟩
• 
  Elodie Girard, Séverine Eon‐marchais, Robert E Olaso, Anne‐laure Renault, Francesca Damiola, et al.. Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing. International Journal of Cancer, 2019, 144 (8), pp.1962-1974. ⟨10.1002/ijc.31921⟩. ⟨inserm-02438452⟩
• 
  Mary Beth Terry, Yuyan Liao, Karin Kast, Antonis C. Antoniou, Jasmine Mcdonald, et al.. The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations. JNCI Cancer Spectrum, 2018, 2 (4), pky078. ⟨10.1093/jncics/pky078⟩. ⟨inserm-02438434⟩
• 
  Mary Beth Terry, Catherine Noguès, Daniel Barrowdale, Debra Frost, Carole Brewer, et al.. Alcohol consumption, cigarette smoking, and risk of breast cancer for BRCA1 and BRCA2 mutation carriers: results from The BRCA1 and BRCA2 Cohort Consortium: Alcohol and smoking and breast cancer risk for BRCA carriers. Cancer Epidemiology, Biomarkers and Prevention, 2019, 27, cebp.0546.2019. ⟨10.1158/1055-9965.EPI-19-0546⟩. ⟨inserm-02438388⟩
• 
  Amélie Guihot, Anne-Geneviève Marcelin, Marie-Ange Massiani, Assia Samri, Cathia Soulié, et al.. Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer. Annals of Oncology, 2018, 29 (2), pp.517-518. ⟨10.1093/annonc/mdx696⟩. ⟨hal-02163559⟩
• 
  Sophie Blein, Laure Barjhoux, Francesca Damiola, Marie-Gabrielle Dondon, Séverine Eon-Marchais, et al.. Targeted Sequencing of the Mitochondrial Genome of Women at High Risk of Breast Cancer without Detectable Mutations in BRCA1/2. PLoS ONE, 2015, 10 (9), pp.e0136192. ⟨10.1371/journal.pone.0136192⟩. ⟨inserm-01991386⟩
• 
  Eve Bureau, Isabelle Pellegrini, Catherine Noguès, Christine Lasset, Claire Julian-Reynier. “Maybe they have found something new” participants’ views on returning cohort psychosocial survey results. Health Expectations, 2015, 18 (6), pp.2425-2436. ⟨10.1111/hex.12211⟩. ⟨inserm-01991364⟩
• 
  Renaud Sabatier, Véronique Diéras, Xavier B. Pivot, Etienne Brain, Henri Roche, et al.. Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer. Breast Cancer Research and Treatment, 2018, 50 (4), pp.1226-1237. ⟨10.4143/crt.2017.446⟩. ⟨inserm-01985845⟩

43

59